Re: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers
- PMID: 34949515
- DOI: 10.1016/j.ejca.2021.10.037
Re: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers
Conflict of interest statement
Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Comment in
-
Reply to: Letter comments on: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.Eur J Cancer. 2022 Feb;162:243-244. doi: 10.1016/j.ejca.2021.10.038. Epub 2021 Dec 4. Eur J Cancer. 2022. PMID: 34876300 No abstract available.
Comment on
-
Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.Eur J Cancer. 2021 Aug;153:234-241. doi: 10.1016/j.ejca.2021.05.005. Epub 2021 Jul 2. Eur J Cancer. 2021. PMID: 34225229
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials